ENDRA Life Sciences Inc. (NDRA)
$5.04-1.95%Close
SELLCRISIS · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4M
- Beta
- -0.07
- P/E (TTM)
- -0.80
- Short % float
- 4.14%
- Days to cover
- 1.0
- SI change
- -9.9%
- 1W
- -16.56%
- 1M
- -14.14%
- vs SPY 1W
- -16.42%
- vs SPY 1M
- -16.65%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 12
- VALUE
- 11
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-134.9%
REV YoY-
ROE-224.8%
EPS YoY-
ROA-74.5%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.80
P/E FWD-
SECTOR PE20.34
INDUSTRY PE31.41
P/B1.06
P/FCF-
EV/EBITDA-0.69
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E6.80
ALTMAN Z-
CURR RATIO7.10
ND/EBITDA-
BETA-0.07
Company news
FAQ
- What is LOPJLB’s current signal on NDRA?
- LOPJLB’s latest quantitative signal on ENDRA Life Sciences Inc. (NDRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NDRA in?
- ENDRA Life Sciences Inc. (NDRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ENDRA Life Sciences Inc. (NDRA) do?
- ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitorin…